Disease target identification and validation
The company identifies previously unidentified targets and targets previously known or suggested to be associated with a disease state.
Source: LinkedIn company description · Retrieved October 13, 2026
Pure MHC is a platform technology company focused on identifying and validating disease-specific targets for immunotherapeutic drug development in cancer, infectious disease and autoimmune disease.
Its technology provides access to proteins synthesized or degraded inside a cell, including proteins not expressed on the cell surface.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company identifies previously unidentified targets and targets previously known or suggested to be associated with a disease state.
Source: LinkedIn company description · Retrieved October 13, 2026
Its T Cell Receptor mimic antibodies can be optimized for disease treatment, diagnostics or pre-clinical development assays.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 18, 2026, October 7, 2026 and October 9, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.